OCUGEN, INC. Other Asset Impairment Charges
OCUGEN, INC. (OCGN) reported Other Asset Impairment Charges of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OtherAssetImpairmentCharges · last filed 2025-03-05
- OCUGEN, INC. other asset impairment charges for the quarter ending 2024-12-31 was $0.00.
- OCUGEN, INC. other asset impairment charges for the quarter ending 2024-09-30 was $0.00.
- OCUGEN, INC. other asset impairment charges for the quarter ending 2023-12-31 was $0.00.
- OCUGEN, INC. other asset impairment charges for the quarter ending 2023-09-30 was $0.00.
- OCUGEN, INC. other asset impairment charges for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- OCUGEN, INC. other asset impairment charges for fiscal 2023 was $4.07M.
- OCUGEN, INC. other asset impairment charges for fiscal 2022 was $0.00.
| Period end | Other Asset Impairment Charges 3 month | Other Asset Impairment Charges 6 month | Other Asset Impairment Charges 9 month | Other Asset Impairment Charges 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $0.00 derived: sum of 2 quarters · filed 2025-03-05 | $0.00 10-K · filed 2025-03-05 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 10-Q · filed 2024-11-14 | ||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-08 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $0.00 derived: sum of 2 quarters · filed 2025-03-05 | $4.07M 10-K · filed 2025-03-05 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $4.07M 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | $4.07M 10-Q · filed 2024-08-08 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-K 9 month · filed 2024-04-16 | $0.00 derived: sum of 2 quarters · filed 2024-04-16 | $0.00 10-K · filed 2024-04-16 | |
| 2022-09-30 | $0.00 derived: 10-K 9 month − 10-K 6 month · filed 2024-04-16 | $0.00 10-K · filed 2024-04-16 | ||
| 2022-06-30 | $0.00 10-K · filed 2024-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |